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Loss-of-Function ENPP1 Mutations Cause
Both Generalized Arterial Calcification of Infancy
and Autosomal-Recessive Hypophosphatemic Rickets
Bettina Lorenz-Depiereux,1 Dirk Schnabel,2 Dov Tiosano,3,4 Gabriele Ha¨usler,5 and Tim M. Strom1,6,*
The analysis of rare genetic disorders affecting phosphate homeostasis led to the identiﬁcation of several proteins that are essential for
the renal regulation of phosphate homeostasis; for example, ﬁbroblast growth factor 23 (FGF23), which inhibits renal phosphate reab-
sorption and 1,25-dihydroxyvitamin D synthesis. Here, we report presumable loss-of-function mutations in the ENPP1 gene (ectonu-
cleotide pyrophosphatase/phosphodiesterase) in members of four families affected with hypophosphatemic rickets. We provide
evidence for the conclusion that ENPP1 is the fourth gene—in addition to PHEX, FGF23, andDMP1—that, if mutated, causes hypophos-
phatemic rickets resulting from elevated FGF23 levels. Surprisingly, ENPP1 loss-of-functionmutations have previously been described in
generalized arterial calciﬁcation of infancy, suggesting an as yet elusive mechanism that balances arterial calciﬁcation with bone miner-
alization.Hypophosphatemia is a heterogeneous disease with an
incidence of 1 in 20,000 newborns. The majority of
patients are affected by the X-linked form of hypophos-
phatemia (XLH [MIM 307800]) caused by PHEX muta-
tions.1 Singular cases have been reported with mutations
in FGF23 (ADHR [MIM 193100])2 and DMP1 (MIM
241520),3 which show autosomal-dominant and -recessive
inheritance, respectively. Mutations in all three genes lead
to increased FGF23 plasma levels. Functional analysis indi-
cated that FGF23, which is expressed by osteocytes, is a key
regulator of phosphate reabsorption and of 1,25-dihydrox-
yvitamin D synthesis in the proximal renal tubules.4,5
Cases of hypophosphatemia remain, including familial
and consanguineous ones, which do not show mutations
in any of these three genes, suggesting further genetic
heterogeneity.
Here, we identiﬁed three different homozygous, presum-
able loss-of-functionmutations in ENPP1 that were present
in ﬁve individuals with hypophosphatemic rickets and
were not present in 359 controls. ENPP1 is a major gener-
ator of extracellular pyrophosphate (PPi), which inhibits
hydroxyapatite crystal deposition and growth.6 Further-
more, overexpression of ENPP1 has been involved in
type 2 diabetes mellitus.7 Surprisingly, inactivating muta-
tions in this gene have previously been described to cause
generalized arterial calciﬁcation of infancy (GACI [MIM
208000]), a severe autosomal-recessive disorder with a hy-
permineralizing phenotype.8 That both GACI and hypo-
phosphatemic rickets are caused by loss-of-function muta-
tions is most strongly supported by our observation of
a single family, in which the father has hypophosphatemic
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The Americahypophosphatemia, although both carry the same homo-
zygous ENPP1 mutation.
We investigated a cohort of 60 index cases who were
referred to us because of hypophosphatemia and were
proven negative for PHEX, FGF23, and DMP1 mutations.
We ﬁrst performed genome-wide linkage analysis by using
SNP array genotyping in two familial cases (families 1 and
2). Assuming that the disease alleles could be identical by
descent in each family, we analyzed the data by homozy-
gosity mapping and identiﬁed a 4.1 Mb candidate region
on chromosome 6q23 between SNPs rs9388766 and
rs6569926 containing approximately 35 genes, among
them the ENPP1 gene. We considered ENPP1 a candidate
because hypophosphatemia has been reported to occur
in some patients with GACI and to alleviate arterial calciﬁ-
cation in these patients.9 We therefore searched for ENPP1
mutations by direct sequencing in all 60 index cases and
identiﬁed three different homozygous, presumable loss-
of-function mutations in ENPP1 in the two families used
for homozygosity mapping and in two additional families.
Each of the unaffected parents, when available, were
heterozygous for the respective mutation (Figure 1 and
Table 1). The two affected brothers in family 1 carried
a homozygous deletion of the last two exons of ENPP1
(exons 24 and 25, c.2445-798_2778*867del), truncating
the C-terminal part of the nuclease-like domain of the
protein. Sequencing of a junction fragment revealed
a 5615 bp deletion at chromosome 6 from position
132,248,597 to 132,254,212 (according to the UCSC
Genome Assembly build hg18). The breakpoints lie within
single-copy sequences in intron 23 and the 30 UTR. The
affected individual in family 3 had a homozygous 1 bph Center for Environmental Health, 85764 Neuherberg, Germany; 2Depart-
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Figure 1. ENPP1 Mutations in Four Families with Autosomal-
Recessive Hypophosphatemia
The different clinical phenotypes are indicated by half ﬁlled boxes;
light gray:GACI, dark gray:rickets and black:hypophosphatemia.
DNA was available from all patients labeled with a DNA identiﬁer.
Patient 23320 and his son 24384 in family 4 carry the same homo-
zygous ENPP1 mutation, but with different clinical outcome.
Table 1. ENPP1 Sequence Variations
Sequence
Variation Patients Position







exon 24–25 - - -
c.2248_2249insA
(p.S750KfsX6)






exon 8 0 0 0
Heterozygous Variations
c.314-64G>A 11965 intron 2 0 0 0
c.556þ3C>A 25552 intron 4 0 0 0
c.1091þ130G>A 11965 intron 10 0 0 0
c.1329T>C
(p.D443D)
11965 exon 13 0 0 0
c.1-10C>T 22061,
12364
50 UTR 9 2 2
c.1-35G>T 30691,
31756
50 UTR 23 3 15
Mutation numbering is based on GenBank entry BC059375 for ENPP1,þ1 cor-
responding to the A of the translation-initiation codon. This numbering is
compatible with the mutation nomenclature in previous ENPP1 mutation
reports.
a 184 European, 83 Turkish, and 92 Israeli-Arabic individuals were used as
controls.insertion in exon 22 (c.2248_2249insA), leading to
a premature translation termination codon after ﬁve
amino acids (p.Ser750LysfsX6), disrupting most of the
nuclease-like domain. The probands in families 2 and 4
carried a nonsynonymous sequence variation at the
second nucleotide of exon 8, which substituted a glycine
for a valine (c.797G>T [p.Gly266Val]). This amino acid
residue is located within the catalytic domain of the
enzyme and is highly conserved within vertebrate species.
We also found three heterozygous noncoding variants and
one coding variant that were not present in 718 control
chromosomes (Table 1); three of the variants were found
in an affected individual of African origin (11965). To our
knowledge, all identiﬁed mutations have not been
described in GACI before (Figure 2).9
Hypophosphatemia is assumed to be mediated by
elevated FGF23 plasma levels, which affects expression
and internalization of the renal sodium-phosphate co-
transporters SLC34A1 and SLC34A3 and inhibits 1-alpha-
hydroxylation of 25-hydroxyvitamin D. This is supported
by the observation that FGF23 plasma levels are elevated
or inappropriately high in many patients with hypophos-
phatemia due to mutations in PHEX, FGF23 or DMP1. To268 The American Journal of Human Genetics 86, 267–272, Februaryinvestigate whether hypophosphatemia due to ENPP1
mutations is also mediated by FGF23, we measured
FGF23 plasma levels in all studied individuals with two
different ELISAs, one of them detecting both C-terminal
and intact FGF23 and the other detecting only intact
FGF23. Whereas the values of the C-terminal/intact assay
were in the normal range, the values of the intact assay
were clearly elevated in one individual and were slightly
elevated or in the upper normal range in the remaining
ﬁve individuals (Table 2). These ﬁndings are similar to
those observed in XLH. Although only some of the affected
individuals show FGF23 levels above the normal range,
the levels are inappropriately high in the context of low
phosphate serum levels. The phosphaturia observed in
patients with ENPP1 mutations could thus also be FGF23
dependent. Furthermore, given that FGF23 also inhibits
1-alpha-hydroxylation, elevated FGF23 concentrations
could provide an explanation for the inappropriately low
1,25-dihydroxyvitamin D levels observed in all affected
individuals.
Surprisingly, the identiﬁcation of two ENPP1 truncating
mutations and the recessive phenotype suggest loss of
function as the mechanism leading to hypophosphatemic
rickets, the same mutational mechanism that is supposed
to be causative in patients with GACI. We therefore thor-
oughly reexamined the case history and the current disease
status of the ﬁve individuals with hypophosphatemic12, 2010
Figure 2. Position of ENPP1 Mutations
Causing Hypophosphatemic Rickets or
GACI
Distribution of ENPP1 mutations. ENPP1
exons are represented as boxes 1-25. Muta-
tions published previously in patients
with GACI9 are indicated above the gene;
mutations detected in this study are
drawn below the gene. Functional do-
mains are indicated by gray and hatched
areas. TM:transmembrane domain, SO:
somatomedin B-like domain. Asterisk:
rs28933977.rickets. All individuals were diagnosed with rickets in their
childhood and had the characteristic laboratory ﬁndings;
i.e., decreased serum phosphate levels, decresased renal
phosphate reabsorption, and elevated serum alkaline
phosphatase, but normal serum calcium, parathyroid
hormone, and 1,25-dihydroxyvitamin D levels (Table 2
and Table 3). Some of the 1,25-dihydroxyvitamin D levels
are in the upper normal range, but they are far below
values expected in physiological hypophosphatemia.
Furthermore, the severity of the hypophosphatemic
phenotype is documented by the need to perform surgicalTable 2. Chemical and Clinical Data
Family 1 Family 2
19315a 19314a 40897b
FGF23 intact (pg/ml)c 50, 51 49, 55 116, 122
FGF23 C-t RU/mld 82 101 23
Ca (mmol/l) 2.48 2.44 2.28
P (mmol/l) 0.72 (0.97–1.68) 0.74 (0.97–1.68) 0.35 (0.81–1
AP (U/l) 649 (130–550) 656 (130–550) 337 (< 130)
PTH (ng/l) 35.6 24.0 59
25OHD (nmol/l) 157.7 153.5 26.7
1,25(OH)2D (pmol/l) 168.0 235.2 163.2
U Ca/Cr (mmol/mmol) 0.11
TRP (%) 82 83 69
TmP/GFR (mmol/l) 0.68 0.68 0.24






FGF23 levels are current measurements and have been determined in a single labo
results of two or more measurements are provided. All other laboratory investigati
are as follows: Ref. range, reference range; Ca, calcium; P, phosphate; AP, alkal
1,25(OH)2D, 1,25-dihydroxyvitamin D; U Ca/Cr, urine calcium:creatinine ratio; TR
reabsorption to glomerular filtration rate. Informed consent was obtained from all
the Medical Department of the Technische Universita¨t Mu¨nchen.
a Values measured at time of diagnosis before therapy.
b Current measurements after at least 14 days of treatment withdrawal. Reference
age- and sex-dependent values.
c FGF23 intact: assay measuring intact FGF23. Reference ranges for the FGF23 as
mined in our own laboratory for the full-length assay have a mean of 34 and a st
d FGF23 C-t: assay measuring C-terminal and intact FGF23. Reference ranges for
The Americacorrections of bone deformities in three of the affected
individuals. To assess possible arterial calciﬁcations, we
performed ultrasound examinations of the large blood
vessels after the identiﬁcation of the ENPP1 mutations.
The examinations showed normal carotid and renal
arteries and a normal thoracic and abdominal aorta. Neph-
rocalcinosis found in patient 20017 is not typical for GACI,
but it does frequently develop in hypophosphatemia.
However, patient 23320 developed an aortic root dissec-
tion at the age of 28 yrs, and echocardiography after
identiﬁcation of the ENPP1 mutations revealed mildFamily 3 Family 4
Ref. Range20017b 23320a 24384a
41, 48 71, 56 81, 56, 54 10–50
36 33 63 < 120–150
2.5 2.24 2.29 2.15–2.64
.45) 0.49 (0.81–1.45) 0.84 (1.2–1.8) 0.72 (1.05–1.8)
66 (30–115) 818 (< 380) 302 (< 380)
35 62 28.1 12–65
70.2 56.7 45.7 30–120
199.2 118.3 129.8 86–230
0.28 0.51 0.20 < 0.59
97.1 79 83–95






ratory after treatment withdrawal of at least 14 days; for some individuals, the
ons have been performed by the referring hospitals as indicated. Abbreviations
ine phosphatase; PTH, parathyroid hormone; 25OHD, 25-hydroxyvitamin D;
P, tubular reabsorption of phosphate; TmP/GFR, maximum tubular phosphate
study participants. The study was approved by the institutional review board of
values are given in the last column or in parenthesis next to the single values for
says are taken from Yamazaki et al.14 and Imel et al.15 Reference values deter-
andard deviation of 12.5 (n ¼ 28).
the FGF23 assays are taken from Yamazaki et al.14 and Imel et al.15
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Table 3. Summary of Case Histories
Family 1 Family 2 Family 3 Family 4
19315 19314 40897 20017 23320 24384





















Age at diagnosis (yrs) 8 2.5 16.8 6 5.5 ﬁrst week
of lifea
Present age (yrs) 17 11 20 21 35 10
Present height (cm) (SD) 167.3 (1.2) 130 (2.3) 159.6 (2.5) 148 (5) 151.6 (3.6) 112.5 (4)
Sitting height (cm) (SD) 97.3 (þ1.5) 73.2 (0.72) 93.2 (þ2.3)
Leg length (cm) (SD) 70 (3.2) 56.8 (2.5)
Rickets yes yes yes yes yes no










Osteotomy (no. of times) 2 0 5 0 1 0
Time of treatment since diagnosis since diagnosis since diagnosis since diagnosis since diagnosis until





40 mg/kg/d 40 mg/kg/d 40 mg/kg/d 60 mg/kg/d 40 mg/kg/d
1,25(OH)2D
supplementation
15 ng/kg/d 15 ng/kg/d 15 ng/kg/d 15 ng/kg/d
1OHD supplementation 10 ng/kg/d

















at the age of 28 yrs,
which was supplied
with composite craft;
since this time, patient
has received heparin and
b-adrenergic blockers
a Echocardiography within the first week of life revealed increased echogenicity and thickening of the wall of both the abdominal aorta up to the iliac bifurcation
and the kidney arteries. X-ray examination of the shoulder and hip joints showed periarticular calcifications. At the age of 2 wks, bisphosphonate (etidronate 15
mg/kg/d) and low-dose nifedipin treatment was initiated. Under this treatment, cardiac function was stable and blood pressure was within the normal range. At
the age of 12 mo, the patient developed hypophosphatemia and decreased renal phosphate reabsorption. At the age of 4 yrs, he developed necrosis of the hip
joints and labyrinthine deafness, most likely because of calcification of the supplying arteries. This patient was described previously.8
The mutation reported in this paper (c.2320C>T [p.Arg774Cys]) has since been shown to be a polymorphism (rs28933977) with a minor allele frequency of 5%.
Standard deviation scores for height are given in parenthesis. 1OHD, 1-hydroxyvitamin D; 1,25(OH)2D, 1,25-dihydroxyvitamin D.pulmonary stenosis in patient 20017 and thickening of the
aortic valves with incomplete opening in patient 19315.
There was no evidence to indicate that the cardiac alter-
ations occurred as a result of arterial calciﬁcations.
However, arterial alterations without calciﬁcations have
been described in GACI.10 Thus, at diagnosis and during
several years of treatment, the affected individuals showed
clinical and biochemical parameters that were not distin-
guishable from those observed in XLH and ADHR. Current
investigations, however, suggest that these patients are
susceptible to anomalies of the cardiac valves.270 The American Journal of Human Genetics 86, 267–272, FebruaryIn summary, mutations described in this study are pre-
dicted to abolish ENPP1 activity and are associated with
inappropriately high FGF23 plasma levels. ENPP1 is there-
fore the fourth gene that, if mutated, causes hypophospha-
temic rickets due to elevated FGF23 levels.
Two explanations, which can act alone or in combina-
tion, may explain why loss-of-function mutations of
ENPP1 are associated with hypophosphatemic rickets in
some patients and with GACI in others. The ﬁrst explana-
tion is that these phenotypes are expressed to a variable
degree depending on the genetic and environmental12, 2010
Table 4. SLC34A3 and SLC34A1 Sequence Variations
Sequence Variation Patients Position rsSNP MAF Comment
SLC34A1
c.259þ4G>A 19315 intron 3 - NA splice score unchanged
c.774T>C (p.H258H) 40897, 20017, 23320, 24384 exon 7 rs5030873 NA synonymous
SLC34A3
c.757T>C (p.L253L) 19315, 40897 exon 8 rs28407527 0.4–0.435a synonymous
c.942G>C (p.A314A) 23320, 24384 exon 10 rs34664302 0.009a synonymous
c.1009G>A (p.G337S) 23320, 24384 exon 10 rs35699762 0.01–0.37a non-synonymous
Abbreviations are as follows: MAF, minor allele frequency; NA, not available.
a Lorenz-Depiereux et al.16background of the affected individuals. This is the most
likely possibility, because there have been described
patients with a mild GACI phenotype who have both arte-
rial calciﬁcations and concomitant hypophosphatemia
and hyperphosphaturia.9 In addition, we observed in this
study two members of the same family, carrying the
same homozygous ENPP1 mutation, one having hypo-
phosphatemic rickets without arterial calciﬁcations and
the other being affected by GACI with hypophosphatemia.
The identiﬁcation of modiﬁers is unlikely in such a small
number of patients unless their effect is large. We excluded
any obvious sequence mutations in the renal sodium-
phosphate cotransporters SLC34A1 (MIM 182309) and
SLC34A3 (MIM 241530) (Table 4). We detected two
unknown variations in SLC34A1 and three known varia-
tions in SLC34A3. A modifying function of the rare SNPs
rs34664302 and rs35699762 seems to be excluded because
they were present in the two individuals having either
hypophosphatemic rickets or GACI.
The second explanation is that the functional differ-
ences are related to the different mutant alleles. Although
there is no evidence for different isoforms of the ENPP1
protein and in both diseases the mutations are spread
across the entire gene (Figure 2), there remains a possibility
that the effect of the mutations on the protein level is
different for the two phenotypes.
A gain-of-function mechanism is unlikely, however, not
only because of the mutation type but also because of
current functional knowledge. There is evidence that PPi
levels are regulated by opposing actions of ENPP1, which
generates PPi, and tissue-nonspeciﬁc alkaline phosphatase
(TNAP), which degrades PPi into inorganic phosphate.6,11
Because PPi is a potent inhibitor of hydroxyapatite crystal
deposition and osteoblast differentiation, regulation of
ENPP1 expression levels must be tightly controlled. Low
PPi levels result in pathological calciﬁcations, as in patients
with GACI8 and in ttw (tiptoe walking) mice,12 whereas
excess PPi levels leads to calcium pyrophosphate dihydrate
(CPPD) crystal formation, as in idiopathic chondrocalcino-
sis or CPPD deposition disease.13 This phenotype is
different from hypophosphatemic rickets, as is the pheno-The Americatype in a recently described mouse model ubiquitously
overexpressing ENPP1 (Jacobi et al., 2009, J. Bone. Miner.
Res., abstract). Although the functional differences remain
elusive, the identiﬁcation of ENPP1 mutations may have
important consequences for the affected individuals, given
that the current treatment of hypophosphatemia with
phosphorus and 1,25-dihydroxyvitamin D supplementa-
tion may trigger arterial calciﬁcations.Acknowledgments
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